Key result
Increased plasma levels of combined miR-208b and miR-34a were associated with an increased risk of mortality or heart failure within six months after AMI (OR 18.73; 95% CI 1.96-101.23; p=0.000).
Why the study?
Are circulating miR-208b and miR-34a levels on admission associated with left ventricular remodeling and 6-month mortality or heart failure in patients with acute myocardial infarction?
Population
359 consecutive patients with acute myocardial infarction (AMI)
Comparison
Plasma levels of miR-208b and miR-34a assessed… vs Patients without left ventricular remodeling /…
Design
Cohort
Follow-up
6 months
Authors
Loading...
May aid post-AMI risk stratification via miRNA biomarkers; hypothesis-generating and requires prospective validation before clinical use.
Cohort (n=359)
Are circulating miR-208b and miR-34a levels on admission associated with left ventricular remodeling and 6-month mortality or heart failure in patients with acute myocardial infarction?
Odds Ratio: 18.73 (95% CI 1.96–101.23)
p-value: p=0.000
Circulating miR-208b and miR-34a on admission are promising biomarkers for predicting left ventricular remodeling and 6-month risk of mortality or heart failure after acute myocardial infarction.
Lv et al. (2014) conducted a cohort in acute myocardial infarction (AMI) (n=359). Increased plasma miR-208b and miR-34a levels vs. Lower miRNA levels was evaluated on six months mortality or development of heart failure (OR 18.73, 95% CI 1.96-101.23, p=0.000). Increased plasma levels of combined miR-208b and miR-34a were associated with an increased risk of mortality or heart failure within six months after AMI (OR 18.73; 95% CI 1.96-101.23; p=0.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: